Drugs / DISOMOTIDE
DISOMOTIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00254397 | Nov 2005 → Oct 2012 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00334776 | Oct 2003 → Jun 2005 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00072085 | Sep 2003 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DISOMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL263429 ↗ |
| Known as | Disomotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL263429 ↗ |
| Known as | gp100:209-217 (210M) peptide | “gp100:209-217 (210M) peptide emulsified in Montanide ISA-51” NCT00072085 ↗ |
| Known as | MPS-22 | ChEMBL registry synonym — accepted as the source's own label CHEMBL263429 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00072085 ↗ |
| Modality | Peptide | “gp100:209-217 (210M) peptide” NCT00072085 ↗ |
| Route | Subcutaneous | “gp100:209-217 (210M) peptide emulsified in Montanide ISA-51 SC” NCT00072085 ↗ |